# 117-s-164: Advancing Education on Biosimilars Act of 2021

117-s-164, Advancing Education on Biosimilars Act of 2021, is a 117th Congress bill sponsored by Sen. Hassan, Margaret Wood [D-NH] (D-NH); status became_law; PRIA reads it as touching household money (as of 2026-01-05).

- Canonical: https://policyrisk.com/legislation/117-s-164
- As of: 2026-01-05
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 117-s-164
- Congress: 117
- Title: Advancing Education on Biosimilars Act of 2021
- Status: became_law
- Introduced: 2021-02-02
- Sponsor: Sen. Hassan, Margaret Wood [D-NH] (D-NH)
- Cosponsors: 1
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2026-01-05

## Summary

**Education on biosimilars** to help clinicians, patients, and caregivers understand biosimilar and interchangeable biological drugs. It creates an online education program and continuing education for health care providers, and it requires publication of regulators' action packages or summary reviews while protecting trade secrets. - Health care providers get continuing education, webinars, and clinical materials about development pathways, review standards, prescribing considerations, comparability, and how to report adverse events. - Patients and caregivers get an online hub with videos, fact sheets, infographics, and toolkits that explain terms like “biosimilar” and “interchangeable” and how to report problems. - Product sponsors and the public gain continued access to each biological product’s action package or summary review, with explicit protection for trade secrets and confidential commercial information.

## Cosponsors (1)

- Sen. Cassidy, Bill [R-LA] (R-LA), 2021-02-02T00:00:00.000Z

## Votes

| Date | Chamber | Question | Result | Yea | Nay |
| --- | --- | --- | --- | --- | --- |
| 2021-04-14T00:00:00.000Z | house | On Motion to Suspend the Rules and Pass | Passed | 412 | 8 |

## Provisions PRIA read

- More education and transparency on biosimilars: benefit, low. The law advances education on biologic drugs, especially biosimilars. The Secretary may run a website and offer continuing education for doctors, plus materials for patients and caregivers. Topics include what “biosimilar” and “interchangeable” mean, FDA review and licensing standards, and how to r…

## Related bills

- 117-s-4003: Law Enforcement De-Escalation Training Act of 2022
- 117-s-4052: Early Hearing Detection and Intervention Act of 2022
- 117-s-1687: Small Business Cyber Training Act of 2022
- 117-s-1198: Solid Start Act of 2022
- 117-s-1404: Ghost Army Congressional Gold Medal Act
- 117-s-1511: Protecting America’s First Responders Act of 2021

## Sources
- [117-s-164 on Congress.gov](https://www.congress.gov/bill/117th-congress/senate-bill/164)

## Related
- [117-s-4003: Law Enforcement De-Escalation Training Act of 2022](https://policyrisk.com/legislation/117-s-4003)
- [117-s-4052: Early Hearing Detection and Intervention Act of 2022](https://policyrisk.com/legislation/117-s-4052)
- [117-s-1687: Small Business Cyber Training Act of 2022](https://policyrisk.com/legislation/117-s-1687)
- [117-s-1198: Solid Start Act of 2022](https://policyrisk.com/legislation/117-s-1198)
- [117-s-1404: Ghost Army Congressional Gold Medal Act](https://policyrisk.com/legislation/117-s-1404)
- [117-s-1511: Protecting America’s First Responders Act of 2021](https://policyrisk.com/legislation/117-s-1511)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/117-s-164 (as of 2026-01-05).